New Frontiers for an Old Drug: What Is New on the Pleiotropic Effect of Sulodexide in Chronic Venous Disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

1. Advances in sulodexide-based long-term anticoagulation for a myasthenia gravis patient with giant thymoma.Frontiers in pharmacology · 2025
   Review
2. Why Venous Leg Ulcers Have Difficulty Healing: Overview on Pathophysiology, Clinical Consequences, and Treatment.Journal of clinical medicine · 2020
   Review
3. Can Endothelial Glycocalyx Be a Major Morphological Substrate in Pre-Eclampsia?International journal of molecular sciences · 2020
   Review

Corrections and comments

• Comment on
  Sulodexide Improves Contraction and Decreases Matrix Metalloproteinase-2 and -9 in Veins Under Prolonged Stretch.2020

Authors and funding

3 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as